This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: Good afternoon. Thank you for attending today's Agilent Technologies Q3 2022 earnings call. My name is Hannah and I will be your moderator for today's call. All lines will be muted during the presentation portion of the call with an opportunity for questions and answers at the end. If you would like to ask a question, please press star 1 on your telephone keypad. I would now like to pass the conference over to our host, Parmeet Ahuja with Agilent. Please go ahead.
spk11: Thank you, Hannah, and welcome everyone to Agilent's conference call for the third quarter of fiscal year 2022. With me are Mike McMullen, Agilent President and CEO, and Bob McMahon, Agilent Senior Vice President and CFO. Joining in the Q&A after Mike and Bob's comments will be Jacob Tyson, President of the Agilent Life Science and Applied Markets Group, Sam Raha, President of the Agilent Diagnostics and Genomics Group, and Porig MacDonald, president of the Agilent Cross Lab Group. This presentation is being webcast live. The news release for our third quarter financial results, investor presentation, and information to supplement today's discussion, along with the recording of this webcast, are available on our website at www.investor.agilent.com. Today's comments by Mike and Bob will refer to non-GAAP financial measures. you will find the most directly comparable GAAP financial metrics and reconciliations on our website. Unless otherwise noted, all references to increases or decreases in financial metrics are year-over-year and references to revenue growth are on a core basis. Core revenue growth excludes the impact of currency and any acquisitions and divestitures completed within the past 12 months. Guidance is based on exchange rates as of July 31. As previously announced, beginning in the first quarter of fiscal 2022, we implemented certain changes to our segment reporting structure. We have recast our historical segment information to reflect these changes. These changes have no impact on our company's consolidated financial statements. We will also make forward-looking statements about the financial performance of the company. These statements are subject to risk and uncertainties and are only valid as of today. the company assumes no obligation to update them. Please look at the company's recent SEC filings for a more complete picture of our risk and other factors. And now, I'd like to turn the call over to Mike.
spk12: Thanks, Parmeet, and thanks, everyone, for joining our call today. In the third quarter, we once again demonstrated the strength of our diversified business and the unstoppable One Agilent team. We delivered an excellent quarter, significantly exceeding our revenue and earnings expectations. Revenues of $1.72 billion are up 13% core. This is on top of 21% core growth in Q3 of 2021. Third quarter operating margins are 27.5%. Operating margins continue to expand and are up 150 basis points from last year. Earnings per share of $1.34 are up 22%. Our strong results in Q3 coupled with orders continuing to outpace revenues, highlight the ongoing strength of our diversified business. The momentum in our business continues, and we are once again raising our outlook for the year. Let's take a closer look at our Q3 results. From an end market perspective, our results were once again led by strength in our two largest markets, pharma and chemical energy. Our largest market, pharma, grew 16% versus 27% a year ago. Within pharma, Both the biopharma and small molecule segments grew double digits. The momentum in our C&E market segment continues, with Q3 growth of 22%. This is on top of 23% growth a year ago. The C&E market is being fueled by demand in chemicals, along with strong secular demand and ongoing investment within the advanced materials space. We're also very pleased to achieve double-digit growth in the food and environmental and forensic markets, with both markets growing 11%. In our last call, I shared our belief that the business impacts of the Shanghai COVID-19 lockdown would be transitory. I also expressed that we remain confident about the ongoing strength of our business in China. In Q3, the China team delivered 29% growth. These stellar results were driven by continued strong end market demand, coupled with the fast and expected recovery of production and shipment activity following the end of the Shanghai area lockdown. We are also very pleased with its results. which highlights the customer focus, drive, and outstanding execution of the Aslan China team. Strength in America has continued as we post another quarter of double-digit growth on top of 32% growth last year. Our European business grew 6% against a 23% last year, despite a two-point headwind for the curtailment of our operations in Russia. In terms of business unit performance, the life science has an applied revenues of $1.02 billion, up 18% on a core basis. Growth was broad-based, but continued strong demand for our LC and LC-MS offerings, where we posted high 20s growth. Our spectroscopy business grew to low 30s, driven by strength in the advanced materials market. Chemistries and consumables, cell analysis, and our GC business each delivered double-digit growth in the quarter. LSAG's end-market growth was broad-based, with particular strength in the pharma and chemical energy markets. Our farm results are driven by strength in the biopharma segment, which grew more than 20%. We had an excellent showing at the recent ASMS conference, introducing several important LCMS and GCMS instruments and biopharma workflow solutions. These innovative and intelligent LCMS and GCMS systems have been designed to make the lives of our customers easier. The building instrument intelligence and a higher level instrument diagnosis help maximize system uptime and improve lab productivity by allowing operators to focus on their analysis rather than on their instruments. In addition, we introduced an industry-first hydro-inert source for GC single-quad and GC triple-quad instruments, enabling customers to seamlessly migrate from helium as a supplier of gas to lower-cost hydrogen. And rounding out the list of new products announced at ASMS, we introduced the MassHunter BioConfirm 12.0 software, and integrated compliant workflow targeted at the fast-growing oligo-based therapeutic development market. These new products have already been well-received by customers and represent the latest addition to Agile's history of leadership in mass spectrometry. Our LSAG business also won some important awards during the quarter, including the 6560C iMobility LCQ12 system, winning the Scientist's Choice Award for Best New Spectroscopy Product. Earlier this month, we also strengthened and broadened our advanced materials and biopharma portfolio with the acquisition of PSS, Polymer Standard Service, a leader in polymer characterization. We're extremely pleased to welcome the PSS team and their technology to the Agilent family. The Agilent CrossFab Group posted services revenue $359 million. This is up 10% core. We grew 10% core even as lab activity continues to ramp in China. Growth in services was again broad-based across services, contracts, preventive maintenance, compliance, education, and informatic enterprise services. Strong instrument placement and increased connect rates continue to be a driver for our service business as customers continue to see value in our ACG offerings. Another critical important factor in our results is the scale and execution capability of Ashland's world-class global service delivery organization and serve our customers to meet their needs. as is seen as the trusted company to work with among our global customers. The Diagnostic Genomics Group delivered revenue of $340 million, up 3% core. This is the first I compare a 37% growth last year. The solid results in our clinical cancer testing and NGS businesses were partially offset by COVID testing headwinds in a QPCR portfolio. In addition, the DGD business in China continues to ramp from the COVID-related shutdowns there. NASD revenues rubbed modestly in line with expectations. As we noted last quarter, Q3 included the impact of a planned shutdown of our Albuquerque manufacturing line in Frederick, Colorado. The shutdown of Frederick was for both routine maintenance and development of key elements of our Train B, our new manufacturing line that will increase our capacity $150 million-plus when fully ramped. While we continue to make good progress on the construction of Train B, we have seen some supply chain-related delays, and are now targeted at mid-year 2023 go-live, a slight delay. We see continued strong demand for oligo-based therapies as the number of approved drugs continues to increase and the pipeline of drugs in development are targeting disease states with larger patient populations. We are more confident than ever in the long-term trajectory of the market and our business. In addition to these highlights, I'd like to also point at the recent release of Ashland's 2021 ESG report. While we've always published our progress in sustainability and addressing societal needs, this year we've taken our approach to the next level. We address these issues in a new format that, for the first time, that looks specifically at our progress in the areas of environmental, social, and governance issues. We hope you have a chance to review our progress in ESG by checking out the report on the ASLIN website, learning more about how we're executing our mission to advance the quality of life. ASLIN's Q3 results, again, point to the strength of our diversified business and the outstanding execution ability of the Ashland team. We continue to bring innovative, differentiated new offerings to the marketplace. Acceleration in digital orders growth continues, as well as new customer acquisition. In addition, as we started 2022, we undertook a bold move to create one Ashland commercial organization to further drive customer focus and growth. The strength of our portfolio and the continued strong execution by our one Agilent commercial organization make a powerful combination, and you see in the results we're delivering. Customer satisfaction is another all-time high this quarter. We continue to outgrow the market. As a result of our strong Q3 performance and continued momentum, we're once again raising our full-year revenue and EPS guidance. Bob will share more of the specifics. It's an exciting time at Agilent. with the best yet to come. Thank you for being on the call today, and now I will hand the call off to Bob. Bob?
spk13: Thanks, Mike, and good afternoon everyone. In my remarks today, I'll provide some additional details on revenue in the quarter and take you through the income statement and other key financial metrics. I'll then finish up with our guidance for the fourth quarter and fiscal year. Unless otherwise noted, my remarks will focus on non-GAAP results. We are extremely pleased with our Q3 performance. Results were above expectations, and we expect that strength to continue in the fourth quarter. Q3 revenues were $1.72 billion, up 8.4% on a reported basis, and up 13.2% core. FX was a 4.8 point headwind to growth, or $76 million. Pricing for the quarter contributed over three points of growth year on year, and improved sequentially. The performance was broad-based as all end markets and regions grew during the quarter. As we mentioned last quarter, the COVID-related lockdowns in China deferred an estimated $50 to $55 million in revenue from Q2, and we forecasted that revenue would be recovered during the rest of the calendar year. Our team in China did a fantastic job ramping production and shipments faster than expected following the shutdowns. We estimate over half of that deferred total was delivered in Q3, exceeding our expectations. Given this strong performance, we now expect the remainder will be delivered in Q4, which is an acceleration from our thinking from last quarter. The acceleration of the COVID-related shutdown recovery in China contributed to an already strong Q3 for the company. For perspective, we estimate the total business grew double digits, excluding the accelerated recovery. As Mike mentioned, earnings per share of $1.34 are up 22% from a year ago, representing strong incremental flow through of the better than expected revenue growth. This performance is against our most difficult comparison of the year, as EPS grew 41% in Q3 of last year. Now let me dive a little deeper into the end markets. Our largest market, pharma, was up 16%, exceeding our expectations. BioPharma grew 18% and Small Molecule was up 14%. BioPharma is a focus area for us and now represents 38% of our overall pharma business. We expect that ratio to continue to climb over time. In addition, all three business groups grew double digits in the pharma segment. And our LC portfolio continues to perform very well, growing 25% in this important market for us. Chemical and energy continue to show strength, growing 22% during the quarter, driven by the chemicals and advanced materials segments of this market. We saw strengths in plastics and packaging for chemicals and ongoing demand in advanced materials coming from the markets for semiconductors and batteries. In the food segment, we achieved growth of 11% on top of 12% growth a year ago. Strength in the food market was led by the Americas and China. Our environmental and forensics market also grew 11% during the quarter, driven by the Americas and China. In the Americas, we saw increased funding to support PFAS testing, while China experienced faster than expected recovery post the Shanghai shutdowns for GCs and GCMS. The academia and government market grew 5% on top of a 12% comparison last year, in line with expectations. And rounding out the review of our end markets, our business in the diagnostics and clinical market grew 2% against a very strong 28% compare versus last year. While not material at the Agilent level, this market did experience some headwinds associated with COVID related revenues being lower than last year. Excluding this, the growth would have been mid single digits in this quarter. On a geographic basis, China led the way with 29% growth driven by underlying demand and a faster than expected recovery following the COVID-related lockdowns. And looking forward, demand in China continues to be very strong. The Americas grew 11%, another strong showing, and Europe grew 6%, which exceeded expectations. Now, turning to the rest of the P&L, our team continues to execute at a very high level. Third quarter gross margin was 56.4%. up 50 basis points from a year ago as pricing actions, volume, and productivity helped offset inflationary pressures tied to ongoing supply chain challenges and higher logistics costs. Operating expense leverage, driven by the strong top line and continued attention to cost management, helped deliver very healthy margin improvements. Our operating margin was 27.5%, up 150 basis points from last year. Below the line, Our tax rate was 14% for the quarter, as expected, and we had 299 million diluted shares outstanding. Looking at cash flow in our balance sheet, we generated operating cash flow of $326 million in the quarter, while investing $82 million in capital expenditures during Q3, driven by our NASD expansion. During the quarter, we also repurchased $323 million worth of shares, We paid out $62 million in dividends in Q3, returning a combined total of $385 million to shareholders in the quarter. Year to date, we have purchased over $1 billion of shares. Given the ongoing strength of the business, we believe this is a very good investment. Our balance sheet continues to remain healthy with a net leverage ratio of one. Now let's move to our outlook for the full year in the fourth quarter. We now expect revenues for the full year to be in the range of $6.75 to $6.775 billion. This takes into account our Q3 results and an improved outlook in Q4, partially offset by an additional $40 million headwind associated with the strengthening of the dollar. This represents core revenue growth of between 9.9 and 10.3%. We are also raising our EPS guidance for the year to a range of $5.06 to $5.08, representing 17% growth year on year. This translates to Q4 revenue in the range of $1.75 to $1.775 billion. Core growth is expected to be in the range of 10.3% to 11.8%, while exchange rates will be a five-point headwind, and M&A will contribute 0.1 points. In closing out our Q4 guidance, non-GAAP EPS is expected to be in the range of $1.38 to $1.40, up 14% to 16% versus the prior year. This is based on a 14% tax rate and 299 million diluted shares outstanding. The Agilent team once again performed extremely well in Q3, delivering strong results, driving excellent execution, and building a strong foundation for the future. Our diversified business, and most importantly, our team, have put us in an excellent position to again deliver strong results in Q4. And now back to Parmeet as we take your questions. Parmeet?
spk11: Thanks, Bob. Hannah, if you could please provide instructions for the Q&A now.
spk07: Certainly. If you would like to ask a question, please press star followed by one on your telephone keypad. If for any reason you would like to remove that question, please press star followed by two. Again, to ask a question, press star 1. As a reminder, if you're using a speakerphone, please remember to pick up your handset before asking your question. The first question is from the line of Matt Sikes with Goldman Sachs. Please proceed.
spk04: Hey, good afternoon, Mike and Bob. Congrats on the quarter. Good afternoon, Bob. Good afternoon, Matt. Sure. Maybe just starting on LSAC, we had a really good quarter. Just interested to know, one, what drove the operating margin expansion in the quarter relative to your expectations in last year? And then specifically, I know it was broad-based strength across instrument categories, but was there one or two areas that really surprised you to the upside where you feel is either underappreciated or could see continued momentum in the back half of the calendar year?
spk12: Yeah, so I'll take the first part of that, and we'll jump in and have Bob and Jacob add their thoughts here as well. So I think relative to the strength and why the operating margin is so high as one is I think we've benefited from the leverage impact of having those higher than expected revenues. But more importantly, we've been working on the pricing side and really ensuring that we are receiving the value for our offerings. And, Bob, I think we were well over three points of price appreciation overall for the portfolio in LSAG, I believe. That's correct. That's correct. And we are, as you may have picked up in my script, it was across the board great quarter for LSAG and across all product categories. But, Jacob, I think a couple really stood out for you, didn't they?
spk10: Yeah, I think, as we know, we continue to do really well in the LC-LC-MS space, but this quarter it's really the spectroscopy that was standing out. We have, especially in our atomic spectroscopy field, we have really seen a lot of momentum based, of course, on the dynamics in the markets, but also the innovations that have been created over the past years. And I think we really see the impact of that these days.
spk12: Yeah, I think it was a real race to see who had the highest growth rate. Spectroscopy or LC and LC-MS, they both did extremely well. They were close.
spk04: Great. And then maybe just a follow-up. I know Europe. Sure. Yeah, I was going to say for a follow-up. Can you hear me?
spk00: Yes, yes, yes.
spk04: Oh, yeah, sorry. Just for a follow-up on Europe, 6% growth. I think getting a lot of questions on just the spend environment in that region. What are you seeing there? And are there any kind of concerns you might have in terms of, you know, demand either from the currency fluctuations or just overall demand in certain end markets within Europe?
spk12: Yeah, sure, Matt. So, you know, we posted a 6% growth rate, core growth in the third quarter, albeit there was actually two points of headwind from the containment of our rush operation. So it really was high single digit, 8% on a restated basis. And Europe clearly is a watch area for us, but we haven't seen any significant signals of movement to the downside.
spk13: Yeah, I think, Matt, to build on what Mike is saying, I think in particular we continue to see very strong growth in our pharma business, and that really is a global phenomenon. But we also saw very nice growth in our chemical and energy businesses as well. And so, as Mike mentioned, it is a watch area, but the demand, you know, from what we're seeing in the health of the order funnel continues to be there.
spk11: Great. Thanks very much.
spk07: Thank you. The next question is from the line of Brandon Couillard with Jefferies. Please proceed.
spk04: Hey, thanks. Good afternoon. Mike, could you elaborate just on the core order growth that you saw in the third quarter? And given the strength of order momentum over the last several periods, how does that inform kind of your initial thoughts on 23? I mean, should we still think about five to seven still being relevant? And then, Bob, should we expect a normal 30% to 40% incrementals next year? Any headwinds to consider maybe the new NASD line?
spk12: Hey, Brandon, We're probably not ready to talk about 23, but I want to leave you with a couple of thoughts here, which is very clearly the business has momentum. And even though we had the highest revenue quarter ever for Agilent in this recent third quarter, we still built backlog, both globally and also in China. So our orders exceeded our revenues. So it sets us up nicely, I think, for 23, but we'll get to 23 when we get there.
spk13: Yeah, and I think, Brandon, on your core incrementals, I mean, I think that if you look at historically, that's where we've been. Obviously, we do have some startup costs in 23 for NASD, and we'll spell those out when we get to the numbers. But I don't think that there's going to be anything fundamentally different on an incremental basis going forward.
spk04: Okay. That's helpful. And then on the NASD train B line, um, like you said, it's pushed out a little bit in terms of the launch timeline. Is that like one or two months? I thought the plan was already good next year. And could you elaborate a little more specifically on kind of where the supply chain issues exactly what those are that are pushing the delay?
spk12: I think you got the right timeframe in there, which is a month or two. Uh, it's really been sort of specialized, specialized steel, uh, that's required. So, uh, I actually had a chance to see it myself where you go into a room where the steel pipe fitters are working and getting the area ready, and they can't close things off because they're missing one valve or something. So we've had, you know, bits and pieces that have been missing that actually caused us certain delays. I mean, the team's been all over. I think the global supply chains are pretty well publicized, but we thought it was – We thought we should, in a spirit of transparency, let you know we're still on track for revenue coming out of the facility in 23, but maybe a month or two later than we thought initially.
spk13: Yeah, and I think, Brandon, there is one more important piece. I think based on what we know today, you know, we still expect to be at capacity at the exit of FY23 as well in terms of a ramp-up. Great.
spk08: Thank you. Mm-hmm.
spk07: Thank you. The next question is from the line of Vijay Kumar with Evercore ISI. Please proceed.
spk17: Hey, guys. Congrats on a really strong quarter here. Hi, Mike.
spk00: Thank you.
spk17: Congrats on the trend. One, maybe on the guidance here, Q4 at the midpoint is 11% organic. You guys just did 13%. The comps do get easier for Q4. I'm curious, sequentially, when you think about it, is the change just because of the cadence of how the China deferred revenues were recognized more in CQ versus Q4? Let me just talk about the sequential assumptions here for the 4Q guidance.
spk12: Sure, Vijay. And again, we are very, very pleased with the print. So thanks for the feedback. And Bob, we didn't use it in our script, but I think the word prudent may apply to our Q4 guide as well. That's right.
spk13: Yeah, I think, Vijay, if you think about kind of the moving pieces within China, what we did was we pulled forward some of the revenue that was deferred into Q3, but we also pulled Q1 revenue into Q4. So Q4, I would say, didn't have a material change one way or another. We actually feel very good that we're going to realize that full, you know, $50 to $55 million here in the fiscal year versus having it bleed a little into Q1. As Mike said, I mean, we're not out of the woods, certainly in supply chain challenges and in COVID situations. And so we thought at this point in time, you know, a double-digit core growth is very good, but also prudent, as Mike said.
spk17: I love that word prudent. Maybe one now. Some of the moving parts for 23, Mike, and I'm not asking for a guidance, but if I look at pricing contribution, I think we started the year at 100 basis points. We're running at 300 basis points. I think that pricing should continue until it annualizes until mid of next year. You did mention orders coming in about revenues. What is the backlog conversion? Is that a three-month or a six-month or a 12-month visibility that you have from backlog? Any impact from NASD and, sorry, on CNE? Very strong, but obviously with the macro, should we perhaps be prudent for 23?
spk12: Yeah, so great question, BJ. So I think I'd like to – the headline here was, As the way Bob closed off his, Fred Marks, we're building a strong foundation for the future. So we've got, you know, we had record revenues in Q3, yet we still build backlog. And, you know, some of that backlog obviously will carry into 23. And, you know, we, it's probably a three to six month visibility for sure on the revenue coming from the backlog. And Bob, I don't see that. And we agree with your thesis around pricing and impact load. it'll have on our 23 business as well. And Bob, maybe you want to add a few comments?
spk13: Yeah, the only thing, I think you're spot on, Vijay. I would say there's not a material change right now in terms of how we're thinking about NASD. You know, if I think about the various pieces there, they certainly set us up for a, you know, a good momentum going into FY23. Now, there's still some unknowns in terms of kind of the macro environment. But, you know, we're expecting to have stronger than normal backlog. We certainly have that right now and are expecting to continue that into FY23. into 23, and then obviously pricing is continuing to anniversary, and I would expect it to be a higher contributor to growth next year, all things being equal.
spk17: Understood. Thank you, guys.
spk02: Thanks, BJ.
spk07: Thank you. The next question is from the line of Kunit Sudha with SVP. Please proceed.
spk09: Hi, Mike, thanks for taking the questions. So first one, just LSAG, obviously a very strong quarter. I mean, obviously congrats on the quarter here. When you look at the 25% growth that you're seeing in LC, overall the order book being strong, can you maybe just characterize sort of, you know, from an end-to-market perspective, it seems like Biopharma continues to do well, but geographically, can you just characterize, does this, you know, contribution from biopharma China in the quarter? And how should we think about this sort of order book? Can you maybe characterize the order book more geographically? And do you, you know, expect this again, in line with sort of some of the other questions is that, you know, sort of how should we think about this order book flow through and, you know, flowing through into into 2023? Boy, Puneet, you packed in a lot in that one question.
spk12: We'll try to address it. Sorry, Mike. I was going to say, maybe you want to handle that, Bob. But, you know, I think the answer was really across the board. I mean, both, I mean, clearly biopharma and pharma, you know, our portfolio is doing really, really well there. And as I mentioned to the team the other day, we just got the most recent ALDA report, which shows market share movements. And as my Danish colleagues like to say, it was green, as a Danish forest. Did I get that right, Jacob? That's right. That's right, Mike. It was across the board, but I think it's the same story holds geographically well. So it really is a nice global story. But I think it's more than just pharma. I know you're getting some good C&E growth, right, in the advanced materials, LC, LC-MS, You know, we posted some really good numbers in food and the environmental market, which also are big users of LC and LC-MS. I think it was really a broad-based story there, if I remember correctly, Jacob.
spk10: Yeah, correct, Mike. I think we're really seeing good performance across the board, as you were saying, Mike. And we are also seeing that the customers are really interested in our full solutions. I think PFAS is a good example of where we see a lot of interest right now. both right now, but also what we see some of the big bills that is coming through in US where PFAS have a prominent exposure. So we expect to continue to see inventory in that space.
spk13: I think, Puneet, just to build on what Mike and Jacob were saying, I think one of the things you're really seeing come out in Q3 is just the strength and breadth of our portfolio. Why we haven't talked about spectroscopy a lot in the past, you know, it continues to be a very important part of our portfolio and solution set. And I think it fits nicely across multiple end markets. And, you know, the LC and LCMS get a lot of headlines, but we're more than just an LC and LCMS business.
spk09: Got it. Thanks for that. And then just I'll keep it simple from a follow up. Columnar standards acquisition. Can you characterize sort of what's the contribution this year? And, you know, how does that enhance your offering for columns and sort of biomolecules? And how should we think about that overall acquisition overall fitting into the LSAG group? You want to take the first piece of that?
spk13: Yeah, yeah. You know, it's not a material business. We estimate that it's less than $10 million annualized today. You know, that's the 0.1% that we built into our guide for Q4. But more importantly, I think strategically I'll let Jacob talk about the merits of the portfolio and how we think it's going to continue to drive growth for us.
spk10: Yeah, thanks for that. And we have a long-standing relationship with PSS, so we knew exactly their strength. And we've been very impressed with what they've done in the polymer business for a long period of time. And particularly, our interest was intrigued when we also see polymer science going from advanced material into biopharma, where we see a lot of opportunities. PSS have done a wonderful job using our instrumentation together with their columns and also an informatics pack they have built to really go after a segment of the market and also the expertise in the field. They have more than 500 application nodes within this field, so we can really leverage that with the strong presence we have across the globe to really accelerate that business opportunity that they have built up over the past decades, really. Got it.
spk03: Okay, great. Thanks, guys. Congrats again.
spk12: Thank you. Appreciate it.
spk07: Thank you. The next question is from the line of Rachel Vattenstall with JP Morgan. Please proceed.
spk06: Hi, and thanks for taking the questions, and congrats on the next quarter. So first up on China. Thank you. Yeah, great to hear that some of that catch-up in China was pulled forward there, and then you also pointed to double-digit growth in the region for that acceleration recovery. So first off, can you just walk us through specifically what drove that pull forward on the catch-ups and lockdowns? And are you seeing an acceleration of demand at catch-up in China? And then second, how are you thinking about that longer-term growth within China? Could that be a source of upside for the year?
spk12: Great. So I'll start, Bob, here. So I'd have to say It was an extraordinary effort of our team in China. I mean, people sacrificed and worked tremendously hard. We had people coming into our factories and living at the factories. They slept and worked at the factories for an entire period of when before you couldn't really get out beyond, back to your local community. So they did that for several weeks, both in our logistics operations as well as our factories. And that allowed us to get our our global GC production going as well as the import export of our product as well. So I have to say really was extraordinary effort of the team that made that happen. And, you know, we're very optimistic about ability to continue to grow well in China. In Q2, I think we talked about a greater than 20% order rate. We posted a number of 29% growth. In Q3, yeah, we still built backlog in the third quarter in China. So I think we're well positioned for the fourth quarter. And Bob, I'd say that probably does represent a level of upside potentially with things continue to develop as we hope. The wild cards from my perspective are how much money could come into the segment from government stimulus. I know they're talking about some of the things. We haven't seen any specifics, so that would be something that would be there on a positive, but again, our demand really is coming from the core private sector, commercial sector around pharma and CNA. We think those things are sustainable.
spk13: Yeah, exactly, Mike. I think you mentioned Q2 kind of order growth rate, and Q3 was in that same range. And so we're seeing very strong demand and been able to do a fantastic job of, you know, ramping up that capacity, and we expect that to continue into Q4.
spk06: Great to hear. And then last one for me, just on the C&E segment. So 22% growth is quite impressive, and that growth has really continued to accelerate in recent quarters on that end market. So how should we be thinking about that longer-term outlook for C&E, especially given some of the macro dependence on that portfolio?
spk12: Well, we think that the structure of this marketplace has changed over the last few years. And yes, there's still a segment that's tied directly to what happens to the global GDP situation. But we've highlighted in my comments, you know, there's secular demand happening here, particularly in advanced materials when there's investments being made in battery technology, more sustainable materials, semiconductors, onshoring of production. So we think those trends are here for a number of years. Our view is the sector's probably got a higher growth rate than we viewed it having a couple years ago because of the secular aspect of growth and CNA. And Bob, what else might you add there?
spk13: Yeah, I think, as you said, I think one of the things that I think is really important, don't take 22 and build it into your model because we don't think that that growth rate is going to continue. We certainly are pleased with it. But I think the other more important piece is, you know, we have a very strong right to win in the C&E business. We're a leader in this space and feel good about our portfolio. And as Mike said, you know, this is an area that – you know, we are seeing kind of renewed sense in some of these areas that we do think that has many years to come in terms of investment. I might use the word undisputed leader in this space.
spk12: I won't disagree. Thanks for the question, Rachel.
spk07: Great. Thank you. Thank you. The next question is from the line of Derek DeBruin with Bank of America. Please proceed.
spk03: Great. Thanks for taking the question. This is for Derek. I want to follow up on your comments on price. You sort of indicated that price continues to sort of grow as you go through the year. Is that a factor of the timing of when orders are converted to revenues and when you're recognizing those revenues? So is this just more of a... a dynamic of that, or is this an incremental price increase that you're building in as you go through the year? And just, you know, alongside that, any comments you could take in terms of reception to price and pushback in any particular areas where you're able to take more versus less, just sort of, you know, give us an update on the pricing dynamic as you go through the year.
spk13: Yeah, hey, Mike, this is Bob. I'll take that. It's the former. And so when we take price, it takes some time to get through the backlog. And so we're seeing the price realization from the orders, the price increase that we took. that we took back in the beginning of the calendar year. And, you know, really what we're trying to do is cover our costs. And, you know, we're seeing increased logistics costs and increased material costs. And so we've taken it across the board, but also recognizing where the costs are higher, we've taken those prices up higher. We haven't really heard any pushback. I think as evidenced by you know, our strong order growth. And then also we look very closely at cancellations within our order book. And that continues to be very low. And so I think our customers understand why we're having to raise prices because of the inflationary environment. And I think to date, we've been able to actually generate more price than I think we anticipated at the beginning of the year.
spk03: Okay, great. And then for the follow-up, you commented on the balance sheet and sort of getting the leverage lower and lower. I've done a couple of deals here and there in the past couple of years, but they definitely tend to be on the much smaller side. So could you talk about your willingness to lever up a little bit and put a little bit more of that capital in work? And if so, what are the types of assets you're looking for? Are sellers willing to... to engage in this market or the, you know, how are things proceeding on that front, on the BD front? Thanks.
spk13: Yeah, I think we've been public about being willing to take on bigger deals than what we have had historically. I think we're still, we have the benefit of having a very strong balance sheet. We're going to first invest in our business. We think that that's the greatest opportunity, but we're always out on the lookout for M&A. And as you said, I would say the pipeline continues to be healthy. You know, the dynamic has certainly changed in the last nine months, particularly on the public market side. And I think there's some good assets out there. It's probably taken a little longer on the private market side, which is where we tend to focus our efforts. But I can tell you that, you know, we – have the beauty of our model is that, you know, we have organic growth first and M&A is kind of an adder on top of that. And so it is something that we're continuing to look at and would be not uncomfortable levering up a little higher than where we are today for the right deal and if the economics work. Absolutely, Bob.
spk03: Is that three to four times lever or?
spk13: I'm not, that's pretty rich. But, you know, I think it all depends on what the right asset and what it looks like.
spk03: Got it. Thanks.
spk07: Thank you. The next question is from the line of Josh Waldman with Cleveland Research. Please proceed.
spk14: Hey, Josh. Hey, thanks for my, hey, hey. Thanks for taking my questions. Just two for you guys. First, Mike, Mike wondered if you could provide more context on the supply chain situation, you know, how supply and cost attract versus your expectations over the last 90 days. Have you seen any relief on supply? And then it sounds like you've built backlog in Q3. Curious whether your fourth quarter guide assumes any work down in the backlog given recent order rates?
spk12: Yeah, so I'll let Bob handle the second question, and I'll start with the first one. So supply chain challenges are still out there, but our team continues to do an excellent job navigating them, getting the material that we need for our customers. We continue to have very, very low order cancellation rates. It's something we watch like a hawk. And I think we're managing the price changes. So I think in the early days of things, we were kind of surprised at what things would cost on the on the market for chips and others, but I think we've now found ways to work that and then offset that with some of the pricing actions that we mentioned earlier. So I think if anything, it's probably trending in a more positive direction, albeit it's still challenging out there.
spk13: And I would say on the second question, Josh, I would say first and foremost, demand continues to be very strong in our marketplace. And so we're expecting order growth to continue into our fourth quarter. As you know, that typically is one of the larger quarters that we have for our sales organization and certainly for our customers as well. That being said, you know, I would expect maybe some slight degradation in backlog, just given, again, the deferral that we're talking about within China. But don't interpret that as us seeing anything slowing in the marketplace.
spk14: Got it. Then kind of along those lines, wondered if the group has any initial thoughts on pharma budget flushing this year, given the strength in orders from these accounts. You know, curious at this point if you're getting any indication that Maybe the strength in the order book is reflecting pull forward or just not seeing that yet.
spk12: Yeah, Josh, I'm going to pass this call over to Porek. He's the closest to what's going on. As you know, he heads up our one commercialization in addition to running our ECG services business. So, Porek, what's your thoughts on that?
spk01: Yeah, no, I think it's pretty steady. Mike, we're not seeing any pull forward at this point. And of course, the team are very focused on key end markets and workflows where we have the best chance to meet the customer needs. So we're seeing a very steady stage order rate with not much pull forwards.
spk14: Got it. Appreciate it. You're very welcome.
spk07: Thank you. The next question is from the line of Jack Meehan with Nepron Research. Please proceed.
spk02: Thank you. Good afternoon. So I wanted to ask about the chemical and energy. Good afternoon. So the chemical and energy acceleration. My first question is on the chemicals customers. So your commentary sounds pretty bullish. There's certainly been some headlines from some of the big European chemical players that have been a little bit more mixed, though. So it would just be great to get your perspective on how you feel about the durability of that customer class and kind of squaring your view versus what we might be hearing from others in the market.
spk12: Yeah, that may be more regionally specific to Europe, where we did see a level of growth a little bit slower than we've seen in America and China. So I'd say that's probably more regionally specific. And as we mentioned earlier in our call, you know, Europe remains sort of a watch area for us because of obviously obvious challenges in that region right now. But I think we think it's pretty durable right now. I mean, I think it's, You know, remember the chemical pieces going into some of these supply chains, you know, as fabs go up and other things. So it's fueling some of the efforts in the advanced materials area. And Bob, I know that you and Jacob looked at this a little more closely. I don't know if there's anything else you'd add to that.
spk13: No, I think you're spot on, Mike. I mean, if we looked across the – all regions grew in C&E, as Mike, you were saying. But, you know, Europe was below the average. And so – But I think over time, you know, that investment in some of these areas, you know, we think is, you know, ongoing demand.
spk02: Great. And then, you know, it was only a week ago, the Chips and Science Act got signed into law. I'm not sure if you have any early perspectives as to what this might mean for Agilent, if you could call out kind of the businesses that you think, you know, could benefit from some of the funding that's going in. And can you just maybe call out what did the advanced materials business grow this quarter?
spk12: Thanks. Yeah, so I'll let Bob handle the second question. He's got more numbers on the pages than I do in front of him. But relative to the recent enactment by Congress, we see some real upside for us. We actually were just talking about that before this call. I think the big debate is when is it actually going to release. But, you know, Jacob mentioned earlier PFAS. Well, we can see there's some funding in there for PFAS, which will help our LCMS and GCMS business. And then, you know, tied to the chips, you know, both the upstream and downstream side of semiconductor fabs will play right into that spectroscopy strength that we're that we mentioned as well. And Jacob, perhaps you want to add a few others?
spk10: Yeah, I think, I mean, actually, even though spectroscopy and GC are the big winners related to the CHIPS Act, we actually see across the board. It's both the mass spec business, also the LC and LC-MS that Mike was mentioning, and then, of course, a lot of our consumables also. So we see a lot of opportunities here. I think both the CHIP Act, but also the other bill, what's it called, the infrastructure bill and the inflation bill here, all of them are driving some of our technologies. So we see a lot of opportunities in that. Now, it all comes down to timing here.
spk13: And the answer to your last question, it was above 30%. Thanks.
spk02: Okay, super. Thank you, guys.
spk05: welcome jack thank you the next question is from the line of elizabeth garcia with ubs please proceed hey guys thanks so much for taking the question uh congratulations no problem um thank you very much yeah great so so um maybe i just didn't catch it but i know there was the plan shut down this quarter for nas but just thinking about kind of how we should think about kind of uh quote this quarter and then maybe sequentially as we head into the next quarter. For the 4-2.
spk13: Bob, you and Sam on the tag team on this one? Yeah, so we had a plan shut down this quarter. Expect return to strong growth in Q4 for NASD.
spk12: And Sam, I don't know if you want to add some comments about what you're seeing on the market as well?
spk16: Yeah, yeah, thanks, Mike, and thanks for the question. I mean, listen, it was a good quarter. We had the plan shut down, you already heard about. But I want to note that we are very pleased with the trend that we're seeing, that increasingly these very therapeutic oligos that we're working on, that the treatment modalities beyond the more rare indications are expanding into diseases for larger populations. You know, for example, you might have seen just recent news from L-nylin, that reported favorable results on their phase 3 study for paticerine. And this is for patients with ATTR for cardiomyopathy. And as an allanolam supplier for the API and paticerine, you know, we're, of course, excited. We also think this is indicative of just generally the trend that we're starting to see and the promise of therapeutic oligos. And, you know, our book of business remains strong as we go into the quarter and, you know, as we'll go into next year.
spk12: Yep. Hey, thanks, Sam. I probably should have elaborated a little more, Elizabeth, on the routine. I think it's also important to understand why we were shutting down, right? It's both for routine maintenance, but also the critical milestone in the construction of Train B. So we tied the infrastructure together. So that's why we're speaking with confidence about our ability to get revenue in 23. Great.
spk05: Great news. And I guess just one more for me, staying on the theme of kind of biopharma. So you kind of announced the collaboration with APC. or real time process monitoring. We also had an announcement Merck's around downstream PAP. It would be great to kind of get your thoughts around the space and kind of the work you're doing here.
spk12: Yeah, I'll make it some high level comments and then you want to provide some specific as well. So we love this space and we've been putting a lot of our investments over the last several years targeted at the biopharma space. And you see it reflected now in the growth rates and actually how we're shifting the mix of our foreign business, both in the lab. It also plays outside the lab. And Jacob, I know you've got a lot of interesting things happening there.
spk10: Yeah, thanks for that, Mike. And, you know, we are very interesting in the bioprocessing space, especially from the analytical instrument perspective, where we truly believe that instruments will start to move into the manufacturing. You know, historically, we have had in the small molecule space the QAQC sitting in a different lab. And now we see the opportunity to bring Adline Online, LC, and LC-MS technologies into the bioprocessing space itself and manufacturing space itself. And hence, we have decided and we have made collaborations with leaders in that space, Merck being one of them, where we're developing, of course, based on our individual strengths, new solutions to address that. But we're looking at the multiple partnerships in this space here, and we're really bullish around that.
spk05: Great. Thanks so much.
spk12: You're quite welcome. Thank you.
spk08: The next question is from the line of Patrick Donnelly with Citi. Please proceed.
spk04: Hey, guys. Thanks for taking the questions.
spk08: Hey, Patrick.
spk04: Sure. Mike, maybe one for you. Hey, how are you? Sure. Maybe one for you just on China specifically in terms of the linearity of the border. Can you just talk about, I mean, it sounds like things clearly picked up as we went, obviously, on the supply side. You guys kind of got back online. Can you talk about the demand environment as well? You know, obviously you guys are the only ones who have kind of a full July in the quarter. So just curious what kind of ramp you saw throughout the quarter. And then again, as we work our way through August here, I mean, it certainly seems like the order growth has been encouraging, but maybe just talk about how things trended there throughout the quarter going into this quarter.
spk12: Great question. Yeah, sure. I happen to do so. I think it's a great question. And I'll parse my response into two areas, orders and revenues. So I think I would say the order intake throughout the quarter was there. It was linear, smooth, no big lumpiness. In fact, that's what we saw in the second quarter as well. So now, as you know, the revenue side has been a different story because the ability to get product in and out of China as well as produced in China was affected by the COVID-19 shutdowns. That's where we saw maybe a slower start, you know, first few weeks of Q3, but then the team's efforts really started paying off when we were able to get back into our facility. So I think the ramp rate of revenue looked at a little different profile throughout the quarter. And, Bob, I don't know if you'd add anything.
spk13: Yeah, no, that's exactly right. I mean, if you think about the months in our quarters, May was very light. As we talked about, we were ramping up, and I think we exited May at like 25% capacity. And then... the teams really started kicking it in gear as the COVID restrictions started to ease. And July was very strong as they not only got the production up to full capacity, but then were able to not only satisfy existing demand, but also some of that deferral. Right. Bring it in.
spk12: And they were really focused on meeting the expectations of our customers who wanted the product. And as I mentioned earlier in my early comments, You know, we had teams working a lot of overtime, working in the factories over the weekend, so really some heroics that got us back on track.
spk04: Yep, it's encouraging to hear. And then, Bob, maybe one for you just on the margin side. You talked about pricing a few times on the call. Can you just talk about, I guess, the flow through to the margin side? You basically said it's offsetting some of the increasing costs. Maybe just talk about the give and take on that front in terms of pricing increases, the cost increases, and how we should think about kind of that algorithm going forward on the margin piece.
spk13: Yeah, I think if you looked at our 150 basis points year on year, it was roughly 50 basis points in gross margin and then 100 basis points of leverage on the SG&A OPEC side. And I think if you looked at that, you know, if there was some productivity, as I mentioned, price probably would have kept things flat. And then the other 50 basis points were a benefit of some productivity that the OFS team did and then the volume. You know, that's the thing that really – I think really helped drive a benefit in gross margin is just the amount of product that was able to be produced through the factories. And so I think about pricing as covering our costs. And then if those incrementals around better than expected revenues drove the margin improvement. on the gross margin side. What I would say is, you know, we continue to leverage the OPEX side to drive our productivity, you know, as a company overall.
spk08: Helpful. Thank you, guys. Mm-hmm. You're welcome.
spk07: Thank you. The last question is from the line of Tim Daly with Wells Fargo. Please proceed.
spk15: Hey, everyone. Thanks for the time. Just quickly, I wanted to touch back on NASD here. So, you know, if we're just thinking about when we're past the train B build out, things have kind of normalized a bit. You're starting to leverage those investments and upfront costs here. What's the clean run rate margin profile to think about in that business, you know, I guess initially when we get past that capacity build out period?
spk12: Hey, Tim, that question brought a smile to Bob's face. I'll let him answer that. I would say very good. I'll leave it at that. Public company average, right?
spk13: Yes.
spk15: All right. I can work with that. And then I guess just a quick one here on capital allocation. So, you know, another strong quarter of buybacks. You know, just thinking about the go-forward outlook, how should we – be sizing this in our heads. The $1 billion we've already hit in 2022 with a quarter left to go, is that a good base for the out years? Just general thoughts on the capital allocation hierarchy as some assets are probably getting a bit cheaper and more attractive here.
spk13: Yeah, I mean, I think our methodology really hasn't changed. You know, I think what we do is invest for growth first internally, and then we look for value accruing M&A. But if there isn't anything imminent, we're also not going to keep cash on the books. And, you know, if I looked at historically, we've generated roughly 2% of earnings per share growth kind of below the line through share repurchase. And I think that that's probably a fair estimate. way to look at it going forward. But, you know, in terms of, to be very clear, our priorities are investing for growth internally and then M&A before we would do share repurchases. And we're also committed to continuing to grow our dividend as well.
spk15: All right, great. That's it for mine. Thank you.
spk08: You're quite welcome.
spk07: There are no additional questions waiting at this time, so I will turn the call back over to Harmeet for closing remarks.
spk11: Thanks, Hannah, and thanks everyone for joining. With that, we would like to wrap up the call for today. Have a great rest of the day.
spk07: That concludes today's call. Thank you for your participation. You may now disconnect your lines.
Disclaimer